XHKG
6669
Market cap290mUSD
Jun 13, Last price
7.61HKD
1D
-7.20%
1Q
-3.43%
IPO
-59.65%
Name
Acotec Scientific Holdings Ltd
Chart & Performance
P/E
39.84
P/S
3.90
EPS
0.17
Div Yield, %
—
Shrs. gr., 5y
-0.80%
Rev. gr., 5y
33.72%
Revenues
534m
+12.69%
Net income
52m
+260.88%
CFO
0k
P
Profile
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 533,988 12.69% | 473,848 19.80% | 395,545 30.19% | |||
Cost of revenue | 505,750 | 467,824 | 403,495 | |||
Unusual Expense (Income) | ||||||
NOPBT | 28,238 | 6,024 | (7,950) | |||
NOPBT Margin | 5.29% | 1.27% | ||||
Operating Taxes | 321 | (35) | 177 | |||
Tax Rate | 1.14% | |||||
NOPAT | 27,917 | 6,059 | (8,127) | |||
Net income | 52,280 260.88% | 14,487 -79.35% | 70,142 -188.70% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (33,120) | |||||
BB yield | 0.64% | |||||
| Debt | ||||||
Debt current | 33,654 | 35,938 | 12,263 | |||
Long-term debt | 362,178 | 422,056 | 83,305 | |||
Deferred revenue | (260) | |||||
Other long-term liabilities | 8,705 | 260 | ||||
Net debt | (465,102) | (210,839) | (913,697) | |||
| Cash flow | ||||||
Cash from operating activities | (12,883) | (68,755) | ||||
CAPEX | (79,600) | (46,696) | ||||
Cash from investing activities | (319,216) | (49,170) | ||||
Cash from financing activities | (23,207) | (32,866) | ||||
FCF | 18,945 | (309,467) | (223,404) | |||
| Balance | ||||||
Cash | 809,569 | 879,208 | 986,455 | |||
Long term investments | 51,365 | (210,375) | 22,810 | |||
Excess cash | 834,235 | 645,141 | 989,488 | |||
Stockholders' equity | 1,349,816 | (184,186) | (93,989) | |||
Invested Capital | 727,202 | 1,714,711 | 1,403,025 | |||
ROIC | 2.29% | 0.39% | ||||
ROCE | 1.81% | 0.39% | ||||
| EV | ||||||
Common stock shares outstanding | 301,078 | 301,078 | 299,612 | |||
Price | 5.97 -47.07% | 11.28 -34.34% | 17.18 51.23% | |||
Market cap | 1,797,435 -47.07% | 3,396,158 -34.02% | 5,147,326 82.66% | |||
EV | 1,332,333 | 3,185,319 | 4,233,629 | |||
EBITDA | 28,238 | 52,282 | 11,490 | |||
EV/EBITDA | 47.18 | 60.93 | 368.46 | |||
Interest | 9,833 | 1,415 | ||||
Interest/NOPBT | 163.23% | |||||